DSG1 and pemphigus: The half‐life of the circulating IgG antibodies directed against Dsg1/3 or the pathogenic non‐Dsg autoantigens in pemphigus can be reduced by blockade of the neonatal Fc receptor, and phase I studies have shown promising results in pemphigus (Lee et al., 2018).